← All trials
NCT06080555
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 9, 2023
- Primary completion
- Jan 31, 2024
- Completion date
- Mar 31, 2024
- First posted
- Oct 12, 2023
- Last posted
- Nov 22, 2023
- Enrollment
- 84
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ChinaLead sponsor
- Government of ChinaStudy director
- Jinlin UniversityCollaborator
- Government of ChinaOfficial
- Boji Medical Technology Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.